rais pt reflect higher level confid
sustain long term growth target pe rais
center around urolift franchis believ consensu ep estim
may high given fx rate invest spend stock trade
urolift top-lin growth maintain equal weight believ valuat
captur posit outlook
urolift continu outperform account half growth quarter urolift
sale constant currenc increment urolift sale contribut
sale half constant currenc growth manag expect urolift
grow though estim conting consider accrual impli
least favor reimburs sign competit yet
opportun abroad runway look good neotract clearli good deal
lrp reiter may manag outlin long-rang plan includ
constant currenc growth alreadi exceed like come
least high-end view next coupl year given growth
profil urolift concern margin profil manag
reiter confid achiev lrp margin target well bit
comfort low end rang particularli op margin believ
may sale market invest need support urolift growth
model updat move part rais forecast reflect
beat partial off-set increment fx headwind well impact
steril shutdown ep
estim reduc reflect fx headwind also latest
think cadenc margin expans believ street estim may
bit high still see increment competit guidelin
seek inject medtron telescop risk factor well
extent steril issu continu could also risk factor
quarterli annual ep usd
rais usd
return equiti ttm
link barclay live interact chart
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
continu grow modestli deceler
success past deal notabl
neotract urolift vsi help acceler
overal growth believ sale growth
achiev warrant premium pe
stock current reflect equal weight
upsid case could driven greater urolift
vsi sale greater improv profit
improv core busi sale growth
rate accret
downsid case could driven slowdown
urolift sale rel expect challeng
within core busi foreign exchang rate
stronger us dollar higher interest rate
teleflex sale ep ahead street/our expect constant currenc
sale growth driven intervent urolog
though perform broad-bas includ intervent access vascular
access surgic rel estim ep beat function higher
sale gross oper margin improv significantli lower expect
tax rate given strength ytd manag rais constant currenc sale
expect well rais low end ep guidanc net/net remain
equal weight believ valuat continu captur posit outlook
addit detail quarter
million except per share data chang sale constant currenc basi unless otherwis note
intervent urolog urolift sale street
estim y/i full-year guidanc urolift rais
unsurprisingli manag highlight roll-out
urolift margin upgrad roll-out japan wasnt includ lrp
adjust ep reflect growth y/i despit fx headwind
quarter given ytd perform manag rais constant currenc
revenu guidanc vs prior despit worsen fx
increment impact steril shut-down invest
spend manag rais low end ep guidanc
manag re-affirmed lrp target note feel confid ever
achiev goal laid may
third-parti sterigen privat steril facil georgia shut
manag expect disrupt top line impact
full year ep impact
fx headwind greater vs prior contribut lower
report revenu growth guidanc vs prior
sale report constant currenc basi
gross margin y/i reflect increas sale volum
favor product mix benefit cost improv program partial
off-set impact tariff
sg sale y/i reflect invest spend
 sale y/i
oper margin y/i driven gross margin expans
time invest spend volum leverag
adjust tax rate y/i
adjust ep y/i y/i exclud effect fx
sale rais constant currenc growth expect vs prior cite ytd perform higher
urolift sale vs prior vascular intervent access product line off-set third-parti steril issu
impact fx headwind expect vs prior net/net report sale growth expect
margins/ep manag reiter gross margin oper margin guidanc
compani expect interest expens vs prior benefit redempt note manag
lower tax rate expect lower end previou net/net manag rais low
end ep guidanc vs prior includ fx headwind vs prior headwind
associ closur third parti steril facil
takeaway call pleas see note
kstew call note reiter lrp call focus urolift steril impact manta
model post barclay live model link
organ growth adjust sell day
urolift sale million
urolift contribut growth estimate unadjust day
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
